LP232454-1
Extended-spectrum beta lactamase by cefepime to cefepime+clavulanate inhibitory concentration ratio
Active
Description
Extended spectrum beta-lactamase (ESBL) enzymes are resistance enzymes produced by pathogenic organisms such as E. coli and Klebsiella. The presence of ESBLs can be detected by comparing the inhibitory concentration (IC) of a specific antimicrobial, such as cefepime (a 4th generation cephalosporin), cefotaxime, or ceftazidime (both 3rd generation cephalosporins), with the IC of that antimicrobial plus clavulanate, an ESBL inhibitor. Source: Regenstrief LOINC
Basic Part Properties
- Part Name
- Extended-spectrum beta lactamase by cefepime to cefepime+clavulanate inhibitory concentration ratio
- Part Display Name
- ESBL by cefepime to cefepime-clavulanate IC ratio
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2016-11-13
- Construct for LOINC Short Name
- ESBL by cefep to cefep-clav IC rto
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP232454-1
Language Variants Get Info
Tag | Language | Translation |
---|---|---|
zh-CN | Chinese (China) | 头孢吡肟相对于头孢吡肟+克拉维酸抑菌浓度比值法超广谱 beta 内酰胺酶 Synonyms: 头孢吡肟相对于(与、 |
es-ES | Spanish (Spain) | ESBL para la concentración inhibitoria de cefepime frente a la de cefepime-clavulanico |
it-IT | Italian (Italy) | Rapporto della concentrazione inibitoria di cefepime/cefepime e acido clavulanico, beta-lattamici a largo spettro Synonyms: Rapporto della IC del cefepime/cefepime e acido cl |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://